Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-SOD in SOD1-ALS
NCT06351592Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Mar 2032
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of ALN-SOD in amyotrophic lateral sclerosis (ALS) (6 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 228 weeks and Severity of Treatment-Emergent Adverse Events at 228 weeks. Started Aug 2024; status: recruiting.
02
Drugs
ALN-SOD
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06351592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06351592.